Aerosolized type II transmembrane serine protease 2 inhibitor to combat COVID-19: a proposal

Chandan Raybarman; Surajit Bhattacharjee

doi:10.18203/2349-3291.ijcp20214544

Authors

Chandan Raybarman Department of Molecular Biology and Bioinformatics, Tripura University, Suryamaninagar, Tripura, India http://orcid.org/0000-0001-8368-6308
Surajit Bhattacharjee Department of Molecular Biology and Bioinformatics, Tripura University, Suryamaninagar, Tripura, India

DOI:

https://doi.org/10.18203/2349-3291.ijcp20214544

Keywords:

COVID-19, TMPRSS2 inhibitor, Aerosolized treatment

Abstract

Type II transmembrane serine protease (TMPRSS2) is expressed at the cell surface with COVID-19 infection. And COVID-19 infection misuse TMPRSS2 to advance their spread, making this protease potential focuses for intervention in COVID-19 infection. TMPRSS2 blocker may be the appropriate option to arrest cellular entry of COVID-19 by deregulating spike priming. Therefore a trial may be intended to watch the adequacy of aerosolized spraying of TMPRSS2 inhibitors to break the viral entry to the objective cells that empower to break the COVID-19 transmission. Targeting TMPRSS2 through aerosolized TMPRSS2 inhibitor is important to examine a possibly viable remedial technique in the treatment of COVID-19.

Metrics

Metrics Loading ...

References

Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270-3.

Li F, Li W, Farzan M, Harrison SC. Structure of SARS coronavirus Spike receptor-binding domain complexed with receptor. Science. 2005;309:1864-8.

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-80.

Yoshikawa NI, Okamura T, Shimizu Y, Hasegawa H, Takeda M, Nagataa N. TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection. J Virol. 2019;93(6):e01815-8.

Kawase M, Shirato K, van der Hoek L, Taguchi F, Matsuyama S. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J Virol. 2012;86:6537-45.

Coote K, Atherton-Watson HC, Sugar R. Camostat Attenuates Airway Epithelial Sodium Channel Function in Vivo through the Inhibition of a Channel-Activating Protease. JPET. 2009;329(2):764-74.

Dhanani J, Fraser JF, Chan HK, Rello J, Cohen J, Roberts JA. Fundamentals of aerosol therapy in critical care. Critical Care. 2016;20:269.